IRX1 hypomethylation promotes osteosarcoma metastasis via induction of CXCL14/NF-κB signaling
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Osteosarcoma is a common malignant bone tumor with a propensity to metastasize to the lungs. Epigenetic abnormalities have been demonstrated to underlie osteosarcoma development; however, the epigenetic mechanisms that are involved in metastasis are not yet clear. Here, we analyzed 2 syngeneic primary human osteosarcoma cell lines that exhibit disparate metastatic potential for differences in epigenetic modifications and expression. Using methylated DNA immunoprecipitation (MeDIP) and microarray expression analysis to screen for metastasis-associated genes, we identified Iroquois homeobox 1 (IRX1). In both human osteosarcoma cell lines and clinical osteosarcoma tissues, IRX1 overexpression was strongly associated with hypomethylation of its own promoter. Furthermore, experimental modulation of IRX1 in osteosarcoma cell lines profoundly altered metastatic activity, including migration, invasion, and resistance to anoikis in vitro, and influenced lung metastasis in murine models. These prometastatic effects of IRX1 were mediated by upregulation of CXCL14/NF-κB signaling. In serum from osteosarcoma patients, the presence of IRX1 hypomethylation in circulating tumor DNA reduced lung metastasis-free survival. Together, these results identify IRX1 as a prometastatic gene, implicate IRX1 hypomethylation as a potential molecular marker for lung metastasis, and suggest that epigenetic reversion of IRX1 activation may be beneficial for controlling osteosarcoma metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Cancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343
Molecular characterization of the tumor microenvironment in breast cancer
Allinen, M., Beroukhim, R., Cai, L., Brennan, C., Lahti-Domenici, J., Huang, H., Porter, D., Hu, M., Chin, L., Richardson, A., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.010 · Cited by 1,299
Emerging molecular markers of cancer
Sidransky, D. (2002) · Nature Reviews Cancer · doi:10.1038/nrc755 · Cited by 662
Bilioni, A., Craig, G., Hill, C., & McNeill, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502480102 · Cited by 71 · cited 1×
“Further inspection of the CXCL14 promoter revealed 2 predicted IRX1-binding sites (26): site A at –857 bp (ACACCTGT) and site B at –1950 bp (ACATCTGT).”
ZOU, C.-Y., WANG, J., SHEN, J.-N., HUANG, G., JIN, S., YIN, J.-Q., GUO, Q.-C., LI, H.-M., LUO, L., ZHANG, M., et al. (2008) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2008.00756.x · Cited by 37
Self-citation
Cited by
Zhou, Y., Yang, D., Yang, Q., Lv, X., Huang, W., Zhou, Z., Wang, Y., Zhang, Z., Yuan, T., Ding, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20059-6 · Cited by 672
Self-citationp21 produces a bioactive secretome that places stressed cells under immunosurveillance
Sturmlechner, I., Zhang, C., Sine, C. C., van Deursen, E.-J., Jeganathan, K. B., Hamada, N., Grasic, J., Friedman, D., Stutchman, J. T., Can, I., et al. (2021) · Science · doi:10.1126/science.abb3420 · Cited by 295
The Role of DNA Methylation in Cancer
Lakshminarasimhan, R., & Liang, G. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-43624-1_7 · Cited by 259
Xu, Y., Deng, C., Chen, H., Song, Y., Xu, H., Song, G., Wang, X., Luo, T., Chen, W., Ma, J., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-1307 · Cited by 41
Self-citation
Metadata
- Authors
- Lu, J., Song, G., Tang, Q., Zou, C., Han, F., Zhao, Z., Yong, B., Yin, J., Xu, H., Xie, X., Kang, T., Lam, Y., Yang, H., Shen, J., & Wang, J.
- Venue
- Journal of Clinical Investigation
- Published
- 2015-03-30
- Volume
- 125
- Issue
- 5
- Pages
- 1839-1856
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2022674844
- Cited by
- 122
- References
- 6
- FWCI
- 8.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.